Short Interest in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Rises By 23.0%

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) saw a significant increase in short interest during the month of August. As of August 31st, there was short interest totalling 5,460,000 shares, an increase of 23.0% from the August 15th total of 4,440,000 shares. Based on an average trading volume of 444,800 shares, the short-interest ratio is currently 12.3 days.

Reviva Pharmaceuticals Stock Up 3.4 %

RVPH stock traded up $0.04 during midday trading on Tuesday, reaching $1.21. The company’s stock had a trading volume of 14,426 shares, compared to its average volume of 362,978. The business’s 50-day simple moving average is $1.07 and its 200-day simple moving average is $1.95. Reviva Pharmaceuticals has a 52 week low of $0.60 and a 52 week high of $6.80. The stock has a market cap of $33.78 million, a PE ratio of -0.74 and a beta of -0.10.

Reviva Pharmaceuticals (NASDAQ:RVPH) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.02. As a group, equities analysts forecast that Reviva Pharmaceuticals will post -0.98 earnings per share for the current fiscal year.

Institutional Trading of Reviva Pharmaceuticals

An institutional investor recently raised its position in Reviva Pharmaceuticals stock. Vanguard Group Inc. raised its position in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 2.8% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,001,836 shares of the company’s stock after purchasing an additional 26,854 shares during the period. Vanguard Group Inc. owned approximately 3.59% of Reviva Pharmaceuticals worth $3,787,000 as of its most recent filing with the SEC. 63.18% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

RVPH has been the subject of a number of research reports. Maxim Group reissued a “hold” rating on shares of Reviva Pharmaceuticals in a report on Friday, August 16th. HC Wainwright reissued a “buy” rating and issued a $14.00 target price on shares of Reviva Pharmaceuticals in a research note on Thursday, July 11th. Finally, Benchmark restated a “speculative buy” rating and set a $17.00 target price on shares of Reviva Pharmaceuticals in a research report on Monday, August 26th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $14.33.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.